Where mid-infrared spectroscopy meets medicine

20 Dec
2018

DIAFIR in MARSEILLE (Photonic Roadshow)

The fourth event of the Photonic Roadshow was held in Marseille on November 17th. It is an understatement that the meetings were rich. Experts from all countries covered a wide range of topics ranging from medical market trends and needs to photonic technologies, to the transformation of regulatory requirements into value added for products. We […]

27 Oct
2018

Diafir will be present at the next Bio-Europe convention which will take place in Copenhagen from 5 to 7 November 2018

Diafir will be present at the next Bio-Europe convention which will take place in Copenhagen from 5 to 7 November 2018. The 24th edition of BIO-Europe is Europe’s largest partnership conference serving the global biotechnology sector. This year’s BIO-Europe Partnership Event will bring together more than 4,000 participants from more than 60 countries, representing more […]

Diafir

DIAFIR has been incepted in 2011 by a world-renowned team of researchers from Rennes 1 University, France.

DIAFIR has developed the SPID™ platform, a breakthrough proprietary device for patient screening triage. SPID™ analyses the entire metabolic signature spectrum of patient’s blood serum, within minutes, using mid-infrared spectroscopy.

Thanks to its platform, DIAFIR aims to develop and bring to market its revolutionary serum test NASHMIR® for NASH detection.

Our goal is to help save lives through early detection while being minimally invasive to the patient.

 

  • DIAFIR’s vision is to become the standard of care in the way people are routinely checked for NASH (early detection).
  • DIAFIR’s method is easy to implement and at a low cost, currently targeting the obese patients as the first choice for NASH detection.
  • Our proprietary platform SPID™ can be applied on other types of diseases (as a start we are focused on NASH and infectious arthropathies).